Vol. 3, Issue 1, Part A (2021)

The prevalence of coronary artery disease (CAD) has been steadily increasing in India. Percutaneous and surgical revascularization with angina treatment is important for the management of CAD. Revascularization may benefit patients with stable ischemic heart disease (SIHD) by preventing death, myocardial infarction (MI), and unstable angina. Beta-blockers, long-acting nitrates, and calcium-channel blockers are considered as the mainstay of pharmacological treatment of restenosis. Timing from successful coronary angioplasty to the onset of recurrent chest pain is the strongest predictor of angiographic outcomes. Patients presenting with pain between 1 and 6 months following percutaneous coronary intervention (PCI) typically had angina secondary to restenosis, and those presenting with pain for more than 6 months after the procedure were likely to have progression of coronary disease in a vessel other than the target vessel. The consensus stresses on repeat angiography to assess the cause for recurrent angina, re-stratify the patients at risk, and promptly initiate appropriate medical therapy in light of the goals of OPTA medical management.